

>Wake Forest* School of Medicine

Objective

Endoscopic vacuum therapy (EVT) has shown evidence of possibly being a safe and efficacious therapy for various injuries and complications related to the human gastrointestinal tract.

Our goal is to pool together data from various studies to evaluate the safety and effectiveness of EVT in the management of post-bariatric surgery gastric leaks.

Introduction

Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are two common bariatric surgeries for treatment of obesity. Although the complication rate for post-bariatric surgery gastric leaks are low, given how frequently these surgeries are being performed, having safe and effective therapies available for complications is crucial for patient outcomes. Revisional surgeries can significantly increase t risk of mortality in these patients so avoiding them is ideal but if revisional surgery does occur, having post-op management options would be valuable.

Endoscopic vacuum therapy has emerged in recent years a a potential option for management of luminal wounds. EN is based upon endoscopically applying sponges to the area of a leak and negative pressure is applied to draw off fluid and promote granulation tissue formation along with healing. In this study we aim to review and analyze all currently available data on applying EVT to post-bariatric surgery leaks specifically focusing on success rate, complication rate, mean duration of therapy, and number of sponge changes to see if it's a therapy warranting further research.

References

- 1. Archid R, Wichmann D, Klingert W, Nadiradze G, Hönes F, Archid N, Othman AE, Ahmad SJS, Königsrainer A, Lange J. Endoscopic Vacuum Therapy for Staple Line Leaks after Sleeve Gastrectomy. Obes Surg. 2020 Apr;30(4):1310-1315. doi: 10.1007/s11695-019-04269-6. PMID: 31792702.
- 2. Mencio, M.A., Ontiveros, E., Burdick, J.S. et al. Use of a novel technique to manage gastrointestinal leaks with endoluminal negative pressure: a single institution experience. Surg Endosc 32, 3349–3356 (2018). https://doi.org/10.1007/s00464-018-6055-x 3. Markus A, Henrik BJ, Benedikt R, Alexander H, Thomas B, Clemens S, Jan-Hendrik E. Endoscopic vacuum therapy in salvage and standalone treatment of gastric leaks after bariatric surgery. Langenbecks Arch Surg. 2022 May;407(3):1039-1046. doi: 10.1007/s00423-021-02365-9. Epub 2021 Nov 17. PMID: 34787705; PMCID: PMC915156C
- 4. Leeds, S. G. and J. S. Burdick (2016). "Management of gastric leaks after sleeve gastrectomy with endoluminal vacuum (E-Vac) therapy." Surgery for Obesity and Related Diseases 12(7): 1278-1285. 5. Morell B, Murray F, Vetter D, Bueter M, Gubler C. Endoscopic vacuum therapy (EVT) for early infradiaphragmal leakage after bariatric surgery-outcomes of six consecutive cases in a single institution. Langenbecks Arch Surg. 2019 Feb;404(1):115-121. doi: 10.1007/s00423-019-01750-9. Epub 2019 Jan 15. PMID: 30645682
- 6. Pappis, H. 8th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders. OBES SURG 28 (Suppl 1), 1–130 (2018). https://doi.org/10.1007/s11695-018-3200-5

Endoscopic Vacuum Therapy for Treatment of Bariatric Surgery Complications: A Systematic Review and Meta-Analysis

¹Wake Forest Baptist Internal Medicine Residency, ²Univeristy of Toledo Internal Medicine Residency

Studies	Estir	nate (95	% C.I.)	Ev/Trt
Archid 2020	0.875	(0.646,	1.000)	7/8
Christgianni 2018	0.857	(0.707,	1.000)	18/21
Leeds 2016	0.950	(0.815,	1.000)	9/9
Markus 2021	0.900	(0.769,	1.000)	18/20
Mencio 2018	0.833	(0.661,	1.000)	15/18
Morell 2019	0.929	(0.738,	1.000)	6/6
Overall (I^2=0 % , P=0.910)	0.895	(0.830,	0.960)	73/82
Fig	ure 2	: Endo	scopic \	Vacuu
Fig	ure 2: Esti	Endo mate (9	scopic	Vacuu Ev/Tr
Fig Studies Archid 2020	ure 2: Esti	Endo: mate (9	scopic 5% c.I.)	Vacuu Ev/Tr
Fig Studies Archid 2020 Christogianni 2018	ure 2: Esti 0.125 0.190	Endo: mate (9 (0.000 (0.023	SCODIC 5% C.I.) , 0.354)	Jacuu Ev/Tr 1/8 4/2
Fig Studies Archid 2020 Christogianni 2018 Leeds 2016	ure 2: Esti 0.125 0.190 0.050	mate (9 (0.000 (0.023 (0.000	SCODIC 5% C.I.) , 0.354) , 0.358) , 0.185)	Jacuu Ev/Tr 1/8 4/2 0/9
Fig Studies Archid 2020 Christogianni 2018 Leeds 2016 Markus 2021	ure 2: Esti 0.125 0.190 0.050 0.024	mate (9 (0.000 (0.023 (0.000 (0.000	SCODIC 5% C.I.) , 0.354) , 0.358) , 0.185) , 0.089)	Jacuu Ev/Tr 1/8 4/2 0/9 0/2
Fig Studies Archid 2020 Christogianni 2018 Leeds 2016 Markus 2021 Mencio 2018	ure 2: Esti 0.125 0.190 0.024 0.026	Endo: mate (9 (0.000 (0.000 (0.000 (0.000 (0.000	SCODIC 5% C.I.) , 0.354) , 0.358) , 0.358) , 0.185) , 0.089) , 0.098)	Jacuu Ev/Tr 1/8 4/2 0/9 0/2 0/1
Fig Studies Archid 2020 Christogianni 2018 Leeds 2016 Markus 2021 Mencio 2018 Morell 2019	ure 2: Esti 0.125 0.190 0.050 0.024 0.026 0.167	mate (9 (0.000 (0.000 (0.000 (0.000 (0.000	SCODIC 5% C.I.) , 0.354) , 0.358) , 0.358) , 0.185) , 0.089) , 0.098) , 0.465)	Vacuu Ev/Tr 1/8 4/2 0/9 0/2 0/1 1/6
Fig Studies Archid 2020 Christogianni 2018 Leeds 2016 Markus 2021 Mencio 2018 Morell 2019	ure 2: Esti 0.125 0.190 0.050 0.024 0.026 0.167	mate (9 (0.000 (0.000 (0.000 (0.000 (0.000 (0.000	SCODIC 5% C.I.) , 0.354) , 0.358) , 0.358) , 0.358) , 0.358) , 0.358) , 0.358) , 0.358) , 0.358)	Jacuu Ev/Tr 1/8 4/2 0/9 0/2 0/1 1/6

bariatric surgery (specifically sleeve gastrectomy and Roux-en-Y gastric bypass) gastric leaks.

Larger prospective studies appear reasonable and would allow for a more powerful meta-analysis to further evaluate EVT as a potential therapy for bariatric surgery associated complications.

Matthew Agnew, MD¹; David Farrow, MD²; Bryanna Jay, MD²



Wake Forest* School of Medicine

Methods

Pubmed, Embase, and Cochrane were searched from inception to through May 2022 for studies reporting success and complication rates for EVT used for bariatric surgery associated gastric leaks, whether it was for initial therapy or after revisional therapy for SG and RYGB surgeries. We included both retrospective and prospective studies in our analysis. Using I2 we assessed heterogeneity and calculated 95% confidence intervals using fixed or random effect models.

Results and Discussion

Six studies, totaling 81 patients, were included in the analysis. As seen in figure 1., the total clinical success rate was 89.5% (CI: 83-96%. P < 0.001). As seen in figure 2, the adverse event rate among all studies was 4.5% (95% CI: 0.2-8.7%. P = 0.041).

There were 6 adverse events related to EVT noted in this review. The one mortality event that occurred in this review was presumed to be secondary to deconditioning during the recovery period and not EVT itself and thus wasn't counted in adverse outcomes. EVT associated complications were related to bleeding and abscess formation.

Although not noted in the graphs there was great variability in mean duration of therapy (9.8 to 55.3 days) as well as mean number of sponge changes (2.1 to 10.5).

Contact Information

Dr. Matthew Agnew, MD

Wake Forest Internal Medicine Residency

Email: matagnew@wakehealth.edu